Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Federica Cottone
Observed name:
F. Cottone
Institution:
Royal College of Surgeons in Ireland
Observed institution:
Royal College of Surgeons in Ireland
ORCID:
0000-0002-9852-2450
Observed ORCID:
0000-0002-9852-2450
OpenAlex ID:
A5049352116
217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
2022
·
N.T. Ueno
, W. Jacot
, et al.
·
Annals of Oncology
·
24
PDF
186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC)
2023
·
T.N. Fehm
, F. Cottone
, et al.
·
ESMO Open
·
4
PDF
In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma
2024
·
Catherine Murphy
, Laura Devis-Jauregui
, et al.
·
PLoS ONE
·
3
PDF
188P A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor-positive (HR+), HER2-low metastatic breast cancer (mBC)
2024
·
N.T. Ueno
, F. Cottone
, et al.
·
ESMO Open
·
2
PDF
mRNA vaccination using peptide nanoparticles triggers a strong immune response against endogenous GPC2 in a murine neuroblastoma model
2026
·
Ellen King
, Chayanika Saha
, et al.
·
Molecular Therapy Oncology
·
1
539RO Patient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)
2026
·
C.H.E. Barrios
, F. Cottone
, et al.
·
Annals of Oncology
Dna and Mrna Vaccines for Neuroblastoma: Design, Development, and Immunogenicity Testing
2026
·
E. King
, C. Saha
, et al.
·
Cytotherapy
Show more works
View as search
Works count:
8
Citation count:
34
H-index:
3
I10-index:
1
Year
Topic
Type